Culture-expanded MSCs outperform same-day procedures — because structural outcomes require doses only expansion can reach.
TL;DR
The argument is not that same-day procedures are bad — it is that a typical aspirate yields roughly 0.5–2 million MSCs while the outcomes cluster at 20–100 million cells, a dose that is physically unreachable without expansion. Expansion also brings dosing precision, cell characterization, and release-tested quality control that a same-day procedure cannot offer.
Why this matters if you're considering banking
Banked cells are the starting material for expansion. If you want a characterized, release-tested dose later, you store now and expand then. This page is written for partner clinics that already perform same-day procedures: it recruits them to expansion rather than insulting current practice.
Do culture-expanded cells work better than same-day procedures?
For structural outcomes that cluster at 20–100 million cells, yes — because a typical aspirate cannot reach that dose. Symptom-level same-day results still exist.
Culture-expanded MSCs for osteoarthritis: review of 15 RCTs + 11 non-randomized studies (Copp, Robb & Viswanathan 2023)
Copp G, Robb KP, Viswanathan S · Cellular & Molecular Immunology · 2023
Anchor card. 15 RCTs + 11 non-randomized (~610 patients): improved pain/symptoms in 12/15 RCTs vs baseline and 11/15 vs controls; cartilage protection/repair in 18/21 clinical studies; trend toward better outcomes at 20–100 × 10⁶.
Limitation. Review-level evidence; trial heterogeneity in product, dose, and endpoints. Not a head-to-head of expanded vs same-day.
Expanded exogenous MSCs vs microfracture-recruited endogenous cells (Le et al. 2020)
Le H, Xu W, Zhuang X, Chang F, Wang Y, Ding J · Journal of Tissue Engineering · 2020
Mechanistic/review: expanded exogenous MSCs vs microfracture-recruited endogenous cells — richer ECM, targeted cytokine secretion. Not a head-to-head RCT.
Limitation. Mechanistic and review-level, not a head-to-head RCT of culture-expanded vs same-day procedures.
Phase II multicenter randomized controlled clinical trial on the efficacy of intra-articular injection of autologous bone marrow mesenchymal stem cells with platelet rich plasma for the treatment of knee osteoarthritis
Lamo-Espinosa JM, Blanco JF, Sánchez M, Moreno V, Granero-Moltó F, Sánchez-Guijo F, Crespo-Cullel Í, Mora G, Delgado San Vicente D, Pompei-Fernández O, Aquerreta JD, Núñez-Córdoba JM, Sola MV, Valentí-Azcárate A, Andreu EJ, del Cañizo MC, Valentí-Nin JR, Prósper F · Journal of Translational Medicine · 2020
Lamo-Espinosa 2020, J Transl Med: phase II RCT, 100 × 10⁶ autologous BM-MSCs + PRGF vs PRGF alone; MSC arm outperformed at 12 months.
Limitation. Single-center; PRGF co-intervention in both arms. Does not compare expansion vs same-day BMAC.
Phase I/II long-term follow-up: 10 × 10⁶ vs 100 × 10⁶ BM-MSCs vs hyaluronic acid (Lamo-Espinosa 2018)
Lamo-Espinosa JM, Mora G, Blanco JF, et al. · Journal of Translational Medicine · 2018
Lamo-Espinosa 2018, J Transl Med: phase I/II long-term follow-up, 10 × 10⁶ vs 100 × 10⁶ vs hyaluronic acid; high dose best. Together with 2020 this is the dose-response pair — not the conflated 2021 draft description.
Limitation. Small early-phase trial. Dose-response inside expanded cells, not expanded vs same-day.
Do same-day procedures fail?
No. That is not the claim. Some BMAC/SVF trials show symptom-level benefit. The gap is dose and characterization for structural outcomes.
Same-day BMAC/SVF procedures do show positive symptom-level results in some trials. Mark to select one or two representative citations; until then this note stands. The claim is dose-dependent structural outcomes, not “same-day doesn’t work.”
What would change our verdict
Adequately powered head-to-head RCTs of culture-expanded MSCs versus same-day BMAC/SVF at matched indication, showing equivalent structural outcomes at the 0.5–2 million cell dose.
Why this confidence grade
Class-level and dose-response evidence is strong (Copp 2023; Lamo-Espinosa 2018 and 2020). Direct expanded-versus-same-day head-to-head RCTs are scarce — that is why this is Moderate-to-High, not High.
Reviewed by Mark Katakowski, PhD · Last reviewed August 26, 2026